Drug Trial Radar · NCT03228108
Culture-guided Antimicrobial Prophylaxis in Men Undergoing Prostate Biopsy.
Last checked: Nov 20, 2026Latest source record: May 10, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,538
Actual
Start
Apr 3, 2018
Primary completion
Sep 26, 2021
Study completion Sep 26, 2021
Sponsor
- Lead sponsor
- Radboud University Medical CenterAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- ZonMw: The Netherlands Organisation for Health Research and Development
- First posted
- Jul 24, 2017
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- Male only, from 18 years, up to 90 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study aims to assess the effectiveness and cost-effectiveness of rectal swab culture-guided antimicrobial prophylaxis to reduce infectious complications after transrectal prostate biopsy. Half of participants will receive routine empirical prophylaxis with oral ciprofloxacin (control group), while the other half will receive rectal culture-guided oral antibiotic prophylaxis (intervention group). In the intervention group, men whose rectal swabs do not show ciprofloxacin-resistant bacteria will receive ciprofloxacin prophylaxis, comparable to the control group. In case of ciprofloxacin-resistant bacteria an alternative oral antibiotic based on the culture results will be prescribed (trimethoprim/sulfamethoxazole, fosfomycin or pivmecillinam/augmentin). The investigators hypothesise that the targeted prophylaxis group (intervention group) will have a lower rate of post-biopsy infectious complications compared to the control group.
Conditions
- Complication
- Infection
- Prostate Cancer
Interventions
CiprofloxacinDrug
see study arms.
Trimethoprim/SulfamethoxazoleDrug
see study arms.
FosfomycinDrug
see study arms.
Pivmecillinam/augmentinDrug
see study arms.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Any registered clinical infectious complication after prostate biopsyTime frame: within 7 days post-biopsy
Locations
13 sites in 1 country. Site status is shown where the registry gives one.
Jeroen Bosch Hospital
's-Hertogenbosch, Netherlands
Rijnstate
Arnhem, Netherlands
Bravis
Bergen op Zoom, Netherlands
Amphia Hospital
Breda, Netherlands
Catharina Hospital
Eindhoven, Netherlands
Zuyderland Hospital
Heerlen, Netherlands
Canisius Wilhelmina Hospital
Nijmegen, Netherlands
Radboud University Medical Center
Nijmegen, Netherlands
Bravis
Roosendaal, Netherlands
Zuyderland Hospital
Sittard, Netherlands
Elisabeth Tweesteden Hospital
Tilburg, Netherlands
Bernhoven Hospital
Uden, Netherlands
Isala
Zwolle, Netherlands
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.